Palvella Therapeutics, Inc. (PVLA) vs Zymeworks Inc. (ZYME)
A side-by-side comparison of Palvella Therapeutics, Inc. and Zymeworks Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PVLA
Palvella Therapeutics, Inc.
$130.46HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
ZYME
Zymeworks Inc.
$25.71HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
Total return — PVLA vs ZYME
growth of $100 · dividends reinvested · last 2yPVLA +677.4% (+178.8%/yr)ZYME +100.7% (+41.7%/yr)PVLA compounded faster over this window
PVLA ZYME
PVLA vs ZYME: by the numbers
- •ZYME is the larger company ($1.89B vs $1.87B market cap).
- •Both run net losses; PVLA's is the smaller (0.00% vs -404.00% net margin).
Metrics side by side
Valuation
| Metric | PVLA | ZYME |
|---|---|---|
| Forward P/E | N/A | 24.78 |
| P/S ratio | N/A | 50.94 |
| P/B ratio | 8.63 | 23.53 |
Profitability
| Metric | PVLA | ZYME |
|---|---|---|
| Gross margin | 0.00% | 100.00% |
| Operating margin | 0.00% | -87.33% |
| Net margin | 0.00% | -404.00% |
| ROE | -28.45% | -186.63% |
| ROIC | -23.90% | -44.06% |
Growth (annualized)
| Metric | PVLA | ZYME |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 12.35% |
| Total return CAGR (5Y) | N/A | -1.37% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.